Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.

Giovanni MussoAntonio SircanaFrancesca SabaMaurizio CassaderRoberto Gambino

Published in: PLoS medicine (2020)

In T1DM, the risk of DKA and main therapeutic responses to SGLT2i are modified by baseline BMI and insulin resistance, by total insulin dose reduction-to-baseline insulin sensitivity ratio, and by volume depletion, which may enable the targeted use of these drugs in patients with the greatest benefit and the lowest risk of DKA.

Keyphrases

insulin resistance
type diabetes
glycemic control
body mass index
adipose tissue
metabolic syndrome
cancer therapy
high fat diet
polycystic ovary syndrome
skeletal muscle
high fat diet induced
drug induced